Medesis Pharma S.A.
Clinical-stage biotech developing treatments using its AONYS® drug delivery platform.
ALMDP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010844464
- LEI:
- 969500C15M96P00UR648
- Country:
- France
- Address:
- AVENUE DU GOLF, 34670 BAILLARGUES
- Website:
- https://www.medesispharma.com/
- Sector:
- Manufacturing
Description
Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-12-02 08:00 |
MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE CONGRESS ON GENE THERAPY FOR…
|
English | 210.4 KB | ||
| 2021-12-01 18:30 |
MEDESIS PHARMA : Information mensuelle relative au nombre total des droits de v…
|
French | 220.8 KB | ||
| 2021-11-22 00:48 |
TREATMENT FOR SEVERE FORMS OF COVID-19: MEDESIS PHARMA’S PHASE II CLINICAL TRI…
|
English | 144.7 KB | ||
| 2021-11-22 00:48 |
TRAITEMENT DES FORMES GRAVES DU COVID-19 : L’ÉTUDE CLINIQUE DE PHASE II DE MED…
|
French | 188.6 KB | ||
| 2021-11-09 18:00 |
MEDESIS PHARMA : Information mensuelle relative au nombre total des droits de v…
|
French | 223.5 KB | ||
| 2021-10-07 18:00 |
MEDESIS PHARMA : RAPPORT FINANCIER SEMESTRIEL 2021
|
French | 2.7 MB | ||
| 2021-10-07 18:00 |
MEDESIS PHARMA : Mise à disposition du rapport financier semestriel 2021
|
French | 259.2 KB | ||
| 2021-09-21 18:00 |
TREATMENT OF ALZHEIMER'S DISEASE: ANSM AUTHORIZES MEDESIS PHARMA PHASE II CLIN…
|
English | 458.3 KB | ||
| 2021-09-21 18:00 |
TRAITEMENT DE LA MALADIE D’ALZHEIMER : L’ÉTUDE CLINIQUE DE PHASE II DE MEDESIS …
|
French | 494.2 KB | ||
| 2021-09-16 18:00 |
MEDESIS PHARMA - ACTIVITÉS & RÉSULTATS SEMESTRIELS
|
French | 893.8 KB | ||
| 2021-09-01 19:00 |
MEDESIS PHARMA : Information mensuelle relative au nombre total des droits de v…
|
French | 183.4 KB | ||
| 2021-09-01 17:45 |
MEDESIS PHARMA dépose avec TRANSGENE un brevet européen, fruit de leurs travaux…
|
French | 171.0 KB | ||
| 2021-09-01 17:45 |
MEDESIS PHARMA announces a joint European patent with TRANSGENE
|
English | 163.8 KB | ||
| 2021-08-26 17:45 |
MEDESIS PHARMA : REPOSITIONNEMENT DU PROGRAMME NANOMANGANESE HORS UE APRES UN R…
|
French | 399.3 KB | ||
| 2021-08-26 17:45 |
MEDESIS PHARMA : NANOMANGANESE DEVELOPMENT PROGRAM REPOSITIONNED OUTSIDE OF EU …
|
English | 161.7 KB |
Automate Your Workflow. Get a real-time feed of all Medesis Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Medesis Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Medesis Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-16 | N/A | Other | Sell | 1,000 | 1,170.00 EUR |
| 2024-01-18 | N/A | Other | Sell | 800 | 669.60 EUR |
| 2023-07-21 | N/A | Other | Sell | 1,000 | 1,400.00 EUR |
| 2023-07-04 | N/A | Other | Sell | 5,000 | 7,100.00 EUR |
| 2023-05-23 | N/A | Other | Sell | 3,140 | 6,908.00 EUR |
Peer Companies
